# Tarka® vs. Lotrel® in Hypertensive, Diabetic Subjects With Renal Disease (TANDEM)

> **NCT00234871** · PHASE4 · COMPLETED · sponsor: **Abbott** · enrollment: 357 (actual)

## Conditions studied

- Hypertension
- Diabetes
- Proteinuria

## Interventions

- **DRUG:** trandolapril/verapamil
- **DRUG:** Lotrel (amlodipine/benazepril)

## Key facts

- **NCT ID:** NCT00234871
- **Lead sponsor:** Abbott
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-01
- **Primary completion:** 2005-03
- **Final completion:** —
- **Target enrollment:** 357 (ACTUAL)
- **Last updated:** 2008-07-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00234871

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00234871, "Tarka® vs. Lotrel® in Hypertensive, Diabetic Subjects With Renal Disease (TANDEM)". Retrieved via AI Analytics 2026-08-03 from https://api.ai-analytics.org/clinical/NCT00234871. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*